Assessment
amivantamab
Locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations